Graduate School of Medicine University of Tokyo (Graduate School of Medicine University of Tokyo)

概览

关联

86

项与 Graduate School of Medicine University of Tokyo 相关的临床试验

JPRN-UMIN000053226

/ SuspendedN/AIIT

A Retrospective Multicenter Study Regarding the Risk Factors for Lymph node Metastasis of Gastric Adenocarcinoma of Fundic Gland type - RESECT-GAFG

开始日期2023-12-25

申办/合作机构

Graduate School of Medicine University of Tokyo

JPRN-UMIN000051247

/ SuspendedN/AIIT

National survey of conditional cumulative incidence of complications following liver resection - National survey of conditional cumulative incidence of complications following liver resection

开始日期2023-02-24

申办/合作机构

Graduate School of Medicine University of Tokyo

JPRN-UMIN000048310

/ CompletedN/AIIT

Immediate Necrosectomy vs. Step-up Approach After EUS-guided Drainage of Walled-off Necrosis: a Multicenter Randomized Controlled Trial (WONDER-01) - WONDER-01 study

开始日期2022-06-27

申办/合作机构

Graduate School of Medicine University of Tokyo

100 项与 Graduate School of Medicine University of Tokyo 相关的临床结果

登录后查看更多信息

0 项与 Graduate School of Medicine University of Tokyo 相关的专利（医药）

登录后查看更多信息

1,524

项与 Graduate School of Medicine University of Tokyo 相关的文献（医药）

2025-05-01·Dermatologic Surgery

Fixed Drug Eruption–Induced Hyperpigmentation Treated With High-Fluence Picosecond Alexandrite Laser

Article

作者: Sonoda, Koya ; Omatsu, Jun ; Ishii, Kentaro

2025-05-01·International Journal of Clinical Oncology

Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study

Review

作者: Ozawa, Toshiyuki ; Ishikawa, Masashi ; Maeda, Taku ; Hoashi, Toshihiko ; Shibayama, Yoshitsugu ; Yoshikawa, Shusuke ; Fukumoto, Takeshi ; Nakamura, Yoshiyuki ; Sawada, Yu ; Fujisawa, Yasuhiro ; Ichigosaki, Yuki ; Nakamura, Yasuhiro ; Kishi, Akiko ; Sugihara, Satoru ; Namikawa, Kenjiro ; Uhara, Hisashi ; Kawahira, Hisao ; Katoh, Norito ; Takenouchi, Tatsuya ; Okuyama, Ryuhei ; Ohno, Fumitaka ; Miyagawa, Takuya ; Asai, Jun ; Mori, Shoichiro ; Hatta, Naohito ; Fujimura, Taku ; Shimauchi, Takatoshi ; Iwata, Hiroaki

BACKGROUNDMalignant melanoma (MM) is a rare but aggressive cutaneous cancer, accounting for only 2% of skin cancers in Japan but nearly half of skin cancer-related deaths. While the global incidence of MM is rising, its epidemiology varies significantly by ethnicity and geographic region. In Japan, melanoma incidence remains lower than in Western countries, with acral lentiginous melanoma (ALM) being the most prevalent subtype. However, comprehensive epidemiological and clinical data remain limited.METHODSWe analyzed data from 7442 Japanese melanoma patients collected between 2005 and 2022 through the Japanese Melanoma Study (JMS). Demographic, clinical, and survival data were evaluated, including subtype distribution, TNM staging, and treatment outcomes.RESULTSALM was the most common subtype (40.8%), followed by superficial spreading melanoma (20.2%). Lymph node metastasis was observed in 28.6% of cases, and distant metastasis in 10.9%. The BRAF mutation rate was 27.2%, with significantly lower frequencies in ALM (8.5%) and mucosal melanoma (4.8%). Among Stage IV patients, those treated with both immune checkpoint inhibitors (ICIs) and BRAF(+ MEK) inhibitors demonstrated significantly improved survival compared to chemotherapy alone (P < 0.05). Adjuvant BRAF(+ MEK) inhibitor therapy also resulted in superior relapse-free survival compared to those who did not receive adjuvant therapy (P < 0.005).CONCLUSIONThis study provides the largest dataset of Japanese melanoma patients to date, highlighting distinct epidemiological and clinical characteristics. Given their lower BRAF mutation rates and the limited efficacy of current ICI treatments, these findings emphasize the urgent need for optimize immunotherapy strategies in Japanese melanoma patients.

2025-04-26·Japanese Journal of Clinical Oncology

Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors

Article

作者: Narita, Yukiya ; Fukuda, Takashi ; Yamaguchi, Takuhiro ; Takumoto, Yuki ; Ichihara, Eiki ; Iwata, Hiroji ; Shimozuma, Kojiro ; Kubota, Kaoru ; Shiroiwa, Takeru ; Nakamura, Keiichiro ; Iwamoto, Tetsuya ; Muro, Kei ; Tateishi, Ryosuke ; Hagiwara, Yasuhiro ; Gemma, Akihiko ; Nakata, Akinobu ; Kikawa, Yuichiro ; Kiyota, Naomi ; Minami, Hironobu ; Hotta, Katsuyuki ; Taira, Naruto ; Kato, Kyoko

AbstractElectronic patient-reported outcome (ePRO) monitoring for patients undergoing cancer chemotherapy may provide qualified and early detection of adverse events or disease-related symptoms, leading to improved patient care. The aim of this study is to examine whether addition of ePRO monitoring to routine medical care contributes to improved overall survival and quality of life of cancer patients undergoing chemotherapy. Patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic chemotherapy will be randomized to an ePRO monitoring group and a usual care group. The ePRO group will conduct weekly symptom monitoring using an electronic device after study enrollment until the end of the study. Monitoring results will be returned to medical personnel and used as information for patient care. The primary endpoints are overall survival and health related quality of life. The initial target sample size for the study was 1500 patients. However, due to delays in enrollment, the target was readjusted to 500 patients. Enrollment has been completed, and the study is now in the follow-up phase.

100 项与 Graduate School of Medicine University of Tokyo 相关的药物交易

登录后查看更多信息

100 项与 Graduate School of Medicine University of Tokyo 相关的转化医学

登录后查看更多信息